Alyeska Investment Group L.P. Has $6.83 Million Position in BioNTech SE Sponsored ADR $BNTX

Key Points

• Alyeska Investment Group L.P. dramatically increased its stake in BioNTech SE by 2,769.2%, acquiring an additional 72,386 shares to own a total of 75,000 shares valued at approximately $6.83 million.
• BioNTech reported a revenue increase of 102.6% year-over-year for the recent quarter, with revenue of $306.46 million, despite posting an EPS of ($1.60), missing estimates.
• Major brokerages issued various upgrades for BioNTech, with Truist Financial raising its price target to $155.00, reflecting a positive outlook for the stock among analysts.

Alyeska Investment Group L.P. boosted its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 2,769.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,000 shares of the company's stock after purchasing an additional 72,386 shares during the quarter. Alyeska Investment Group L.P.'s holdings in BioNTech were worth $6,830,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC bought a new stake in BioNTech in the first quarter valued at $455,000. Royal Bank of Canada increased its holdings in shares of BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company's stock worth $653,000 after acquiring an additional 3,514 shares during the period. Nomura Holdings Inc. bought a new stake in BioNTech in the 1st quarter valued at about $2,825,000. DAFNA Capital Management LLC boosted its stake in BioNTech by 23.5% during the 1st quarter. DAFNA Capital Management LLC now owns 10,500 shares of the company's stock valued at $956,000 after purchasing an additional 2,000 shares during the period. Finally, BNP Paribas Financial Markets grew its position in BioNTech by 94.6% in the 1st quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company's stock worth $108,859,000 after purchasing an additional 581,173 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BNTX has been the subject of several analyst reports. Bank of America boosted their price objective on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Leerink Partners set a $112.00 price target on BioNTech in a research report on Monday, June 2nd. Wells Fargo & Company set a $150.00 price target on BioNTech and gave the company an "overweight" rating in a report on Tuesday, August 5th. Truist Financial reaffirmed a "buy" rating and issued a $155.00 price objective (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Finally, HC Wainwright reissued a "buy" rating and set a $136.00 target price on shares of BioNTech in a research note on Monday. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and a consensus price target of $135.80.

BioNTech Price Performance

Shares of NASDAQ BNTX traded down $1.18 during trading on Wednesday, hitting $100.91. The company had a trading volume of 629,877 shares, compared to its average volume of 936,361. The company has a market cap of $24.26 billion, a P/E ratio of -63.08 and a beta of 1.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The business's 50-day moving average is $109.30 and its 200 day moving average is $104.19. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. During the same period last year, the firm earned ($3.36) earnings per share. The firm's revenue for the quarter was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. Equities research analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.